News

Undervaluated TiGenix finishes Phase III of Stem Cell therapy to treat


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Undervaluated TiGenix finishes Phase III of Stem Cell therapy to treat Crohn’s disease


Date: 25/08/2015

Belgium is a real pioneer in developing stem cell therapies. TiGenix pushes this precursor position even further, by presenting good results from a Phase III of its stem cell therapy treating Crohn’s disease.

Founded in 2000, Leuven-based TiGenix developes stem cell therapies for autoimmune and inflammatory diseases. These are based on expanded stem cells extracted from the patient’s adipose tissue. The company has five products in development and one on the market.

For more click here

Source: Labiotech


© Catalyst Innovation Portal 2019